Affluent Medical : Financial results for the first half of 2021 and main clinical update.
Retrieved on:
Mercredi, septembre 22, 2021
ESC, Man, Review, American College of Cardiology, Feedback, FCCP, Death, University, Icahn School of Medicine at Mount Sinai, Silver, Cotignola, Degenerative disease, University of Paris, Mitral valve, FAHA, Heart, Neuro, Group, Education, Committee, Journal, IFRS, Andreas, Cardiovascular disease, Urinary incontinence, EAU, Professor, Company, FESC, Health policy, BJU International, Kalio, Mehran, SAIME, NYHA, The Journal of Urology, Surgeon, COVID-19, Patient, FACC, FACP, American College, Ethics, Adrenal insufficiency, Nature Reviews Urology, Trial of the century, Mount Sinai Hospital, IPO, European Urology, Artus, Animal, Security (finance), Medical device, Pharmaceutical industry, Medicine
During the first half of 2021, purchases consumed fell by 158 thousand compared to the first half of 2020.
Key Points:
- During the first half of 2021, purchases consumed fell by 158 thousand compared to the first half of 2020.
- On 9 June 2021, Affluent Medical announced the success of its IPO on the regulated market of Euronext Paris.
- Starting in 2018 he broadened his field of expertise by engaging in various entrepreneurial projects before joining Affluent Medical.
- Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas.